195 related articles for article (PubMed ID: 37369476)
21. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
Veldman J; Alsada ZND; van den Berg A; Plattel WJ; Diepstra A; Visser L
Br J Haematol; 2021 May; 193(3):506-514. PubMed ID: 33620088
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.
Zijtregtop EAM; Tromp I; Dandis R; Zwaan CM; Lam KH; Meyer-Wentrup FAG; Beishuizen A
Pathol Oncol Res; 2022; 28():1610482. PubMed ID: 36032657
[TBL] [Abstract][Full Text] [Related]
23. Expression Profile of Selected Antitumor Immune Response Genes in Pediatric Classic Hodgkin Lymphoma.
Gul G; Ceyhan M; Ince D; Olgun N; Ozer E
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):358-365. PubMed ID: 35293362
[TBL] [Abstract][Full Text] [Related]
24. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology.
Takahara T; Sakakibara A; Tsuyuki Y; Satou A; Kato S; Nakamura S
J Clin Exp Hematop; 2023; 63(2):58-64. PubMed ID: 37380470
[TBL] [Abstract][Full Text] [Related]
26. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
27. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
[TBL] [Abstract][Full Text] [Related]
28. Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.
Takahashi E; Imai H; Tsuyuki Y; Taniguchi N; Kogure Y; Kataoka K; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Nakamura S
J Clin Exp Hematop; 2023; 63(1):49-57. PubMed ID: 36990776
[TBL] [Abstract][Full Text] [Related]
29. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.
Annibali O; Bianchi A; Grifoni A; Tomarchio V; Tafuri M; Verri M; Avvisati G; Crescenzi A
Sci Rep; 2021 Mar; 11(1):7059. PubMed ID: 33782477
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
31. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
33. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
Jain MD; Kuruvilla J
Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
36. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint CD47 expression in classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Löf L; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Br J Haematol; 2022 Jun; 197(5):580-589. PubMed ID: 35301709
[TBL] [Abstract][Full Text] [Related]
38. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes.
Shokrgozar N; Dehghani M; Golmoghaddam H; Moghadam M; Rezaei N; Moayed V; Arandi N
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e388-e397. PubMed ID: 35098660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
